ADVFN US – Market Content Editor
-
Twist Bioscience Shares Decline Following Quarterly Earnings Miss
Twist Bioscience (NASDAQ:TWST) shares fell 4.2% in pre-market trading after the synthetic biology company reported fiscal third-quarter results that exceeded revenue expectations but fell short of Wall Street’s earnings forecast. The mixed performance prompted investors to focus on the company’s continued profitability challenges despite solid top-line growth. Revenue Beats Expectations, but Earnings Disappoint Twist Bioscience…
-
FDA Awards Breakthrough Therapy Designation to Lilly’s Olomorasib for Pancreatic Cancer
Eli Lilly and Company (NYSE:LLY) has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational drug olomorasib as a standalone treatment for adults with advanced pancreatic cancer carrying a KRAS G12C mutation who have previously received at least one systemic therapy. The designation is intended to accelerate the development and…
-
Nexera Technologies Pursues Exclusive Distribution Rights for Darknet Intelligence Platform
Nexera Technologies Ltd. (NASDAQ:NEXR) has entered into a letter of intent with Nebo Holdings Limited that could see the company become the exclusive global reseller and distributor of Preempt OSINT, a cybersecurity platform designed to monitor darknet activity. The proposed partnership would expand Nexera’s cybersecurity offering by giving it exclusive rights to commercialize the platform…
-
Sportradar Shares Drop After Earnings Miss and Lower-Than-Expected Outlook
Sportradar Group AG (NASDAQ:SRAD) reported second-quarter 2026 results on Monday that fell short of analyst expectations on both earnings and revenue, while its full-year guidance also disappointed investors. The sports technology company’s shares declined 13.20% in pre-market trading following the earnings release. Earnings and Revenue Miss Wall Street Forecasts Sportradar reported adjusted earnings of €0.00…
-
Krystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses Forecasts
Krystal Biotech, Inc. (NASDAQ:KRYS) reported second-quarter 2026 results on Monday that exceeded earnings expectations but fell short of Wall Street’s revenue estimates, sending the stock down 7.65% in pre-market trading. Earnings Outperform While Revenue Comes in Below Expectations The company reported adjusted earnings of $1.79 per share for the second quarter, beating analysts’ consensus estimate…
-
Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) reported second-quarter 2026 results on Monday that fell short of earnings expectations but exceeded revenue forecasts, while also announcing a merger agreement with Indivior Pharmaceuticals (NASDAQ:INDV). The combination of stronger sales, improved guidance and the proposed transaction sent Supernus shares up 18.75% in pre-market trading. Revenue Tops Expectations Despite Earnings Loss…
-
Sally Beauty Shares Slip After Revenue Miss Overshadows Earnings Beat
Sally Beauty Holdings Inc. (NYSE:SBH) reported fiscal third-quarter 2026 results on Monday that exceeded earnings expectations but fell short of Wall Street’s revenue forecast, sending the stock 3.14% lower in pre-market trading. Earnings Beat Estimates While Revenue Falls Short For the quarter ended June 30, 2026, Sally Beauty posted adjusted diluted earnings of $0.55 per…
-
Integer Shares Gain After Earnings Beat and KKR Buyout Announcement
Integer Holdings Corporation (NYSE:ITGR) reported second-quarter 2026 results on Monday that came in ahead of analyst expectations, while also announcing a definitive agreement to be acquired by KKR in an all-cash transaction. The medical device outsourcing specialist saw its shares rise 2.43% in pre-market trading following the earnings release and acquisition announcement. Earnings and Revenue…
-
Marriott Shares Slip Despite Earnings Beat as Revenue Falls Short of Expectations
Marriott International Inc. (NASDAQ:MAR) reported second-quarter results before Monday’s market open that topped earnings forecasts but missed Wall Street’s revenue expectations, sending the hotel operator’s shares down 3.4% in pre-market trading. Earnings Outperform While Revenue Misses Estimates Marriott posted adjusted earnings of $3.19 per share for the quarter, exceeding analysts’ consensus estimate of $3.05 by…
-
TG Therapeutics Raises 2026 Outlook Following Strong Briumvi Sales Growth
TG Therapeutics, Inc. (NASDAQ:TGTX) increased its full-year 2026 revenue guidance after reporting another quarter of strong sales growth for its multiple sclerosis treatment, Briumvi, according to the company’s latest earnings release. The company generated total global revenue of $240.3 million during the second quarter, compared with $141.1 million in the same period last year. Briumvi…